CITY OF HOPE received a $2.3 million R01 research project grant from NCI to fund studies associated with a phase I/II clinical trial in relapsed/refractory adult acute myeloid leukemia. The research team will be led by Steven Rosen, City of Hope’s provost and chief scientific officer.
The phase II clinical trial will test 8-chloro-adenosine in AML patients whose disease has failed to respond to initial chemotherapy. The research will also detail the drug’s mechanism of action, and further characterize the cytotoxic effect of the drug on leukemia stem cells. In addition, researchers will conduct genomic profiling of AML cells to generate gene expression signatures that may help identify patients who may particularly benefit from 8-chloro-adenosine treatment.
The Rising Tide Foundation will fund the clinical trial testing the drug’s safety and efficacy, while the NCI grant will fund correlative studies in genomic profiling and the drug’s mechanism of action in patients.
